and four programs are at the preclinical stage. SOM Biotech applies the proprietary AI-based drug discovery technology for building its pipeline and strategic collaborations with the companies. The AI technology can be applied in any therapeutic area and allows advancing drug candidates into Phase 2a in less than one year (through 505b2 pathway). It also allows improving the effectiveness of drug discovery and drug life cycle management by the identification of novel targets and indications for the molecules.